Tessa Romero
Stock Analyst at JP Morgan
(3.60)
# 771
Out of 4,835 analysts
58
Total ratings
39.53%
Success rate
10.7%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Tessa Romero
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DYN Dyne Therapeutics | Maintains: Neutral | $18 → $17 | $11.75 | +44.68% | 5 | Mar 21, 2025 | |
| BHVN Biohaven | Maintains: Overweight | $72 → $68 | $15.82 | +329.84% | 6 | Mar 5, 2025 | |
| UPB Upstream Bio | Initiates: Overweight | $38 | $8.78 | +332.80% | 1 | Nov 5, 2024 | |
| NMRA Neumora Therapeutics | Downgrades: Neutral | $18 → $15 | $0.67 | +2,152.93% | 4 | Nov 5, 2024 | |
| MCRB Seres Therapeutics | Downgrades: Underweight | n/a | $7.47 | - | 2 | Oct 24, 2024 | |
| SRRK Scholar Rock Holding | Maintains: Overweight | $18 → $31 | $30.83 | +0.55% | 5 | Oct 14, 2024 | |
| CYTK Cytokinetics | Maintains: Overweight | $65 → $71 | $29.84 | +137.94% | 4 | Sep 5, 2024 | |
| EYPT EyePoint Pharmaceuticals | Maintains: Overweight | $32 → $29 | $5.72 | +406.99% | 3 | Aug 13, 2024 | |
| EWTX Edgewise Therapeutics | Maintains: Overweight | $30 → $31 | $14.41 | +115.13% | 8 | Aug 12, 2024 | |
| AGIO Agios Pharmaceuticals | Reinstates: Neutral | $46 | $28.26 | +62.77% | 6 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $29 → $25 | $17.60 | +42.05% | 6 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $2.70 | +640.74% | 1 | Nov 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $8 → $7 | $3.86 | +81.35% | 5 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $54 → $55 | $29.53 | +86.25% | 2 | Apr 25, 2023 |
Dyne Therapeutics
Mar 21, 2025
Maintains: Neutral
Price Target: $18 → $17
Current: $11.75
Upside: +44.68%
Biohaven
Mar 5, 2025
Maintains: Overweight
Price Target: $72 → $68
Current: $15.82
Upside: +329.84%
Upstream Bio
Nov 5, 2024
Initiates: Overweight
Price Target: $38
Current: $8.78
Upside: +332.80%
Neumora Therapeutics
Nov 5, 2024
Downgrades: Neutral
Price Target: $18 → $15
Current: $0.67
Upside: +2,152.93%
Seres Therapeutics
Oct 24, 2024
Downgrades: Underweight
Price Target: n/a
Current: $7.47
Upside: -
Scholar Rock Holding
Oct 14, 2024
Maintains: Overweight
Price Target: $18 → $31
Current: $30.83
Upside: +0.55%
Cytokinetics
Sep 5, 2024
Maintains: Overweight
Price Target: $65 → $71
Current: $29.84
Upside: +137.94%
EyePoint Pharmaceuticals
Aug 13, 2024
Maintains: Overweight
Price Target: $32 → $29
Current: $5.72
Upside: +406.99%
Edgewise Therapeutics
Aug 12, 2024
Maintains: Overweight
Price Target: $30 → $31
Current: $14.41
Upside: +115.13%
Agios Pharmaceuticals
Jun 13, 2024
Reinstates: Neutral
Price Target: $46
Current: $28.26
Upside: +62.77%
Mar 25, 2024
Maintains: Overweight
Price Target: $29 → $25
Current: $17.60
Upside: +42.05%
Nov 28, 2023
Initiates: Overweight
Price Target: $20
Current: $2.70
Upside: +640.74%
Aug 22, 2023
Maintains: Underweight
Price Target: $8 → $7
Current: $3.86
Upside: +81.35%
Apr 25, 2023
Maintains: Overweight
Price Target: $54 → $55
Current: $29.53
Upside: +86.25%